Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
Date:10/22/2008

of Cancer (EORTC), the U.S. National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... NEW YORK, Nov. 30 The ... (MJFF) today announced $1.5 million in total awar...ially disease-modifying therapies for Parkinson,s ...Approaches to Drug Discovery for Parkinson,s Disea...rporation, plc (NYSE: ELN ), a neuroscience-base...
(Date:11/30/2009)... , BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNewswire/...ance document for the publication of company-spons...oday by the British Medical Journal (BMJ). "The pu...the importance of providing support and guidance f... of study results in the peer-reviewed medical lit...
(Date:11/30/2009)...HICAGO, Nov. 30 Dr. Jessica Torren...hington University Medical Center in Washington, D...t-Specific Gamma Imaging (BSGI) in clinical practi...s of breast cancer today at the annual meeting of ...,, "The purpose of the exhibit was to demonstra...
(Date:11/30/2009)... ROCKVILLE, Md., Nov. 30 ... has completed enrollment in the Phase II clinical...009 recommended strains) VLP vaccine candidate in ...lts). This randomized, double-blind, active-contr...and immunogenicity of two different doses (15 mcg ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4
...another salvo into the human-cloning battle, which...ecision to allow therapeutic researchers to grow c... divided vote, the United Nations, Legal Committee...all on all member nations to "prohibit all forms o...with human dignity and the protection of human lif...
... the cost of doing business (CODB) for biotech com...e point of the column was that one of the advantag...nt cost advantage versus setting up shop in other ...ow that the cost of wet lab space in the San Franc... square feet are quoted by month versus by year (l...
... long-term information technology projects into th...pping points, where incremental developments in IT...ucation and other industries. , ,In the days leadi...rch 2 in Madison, several of the state,s IT leader...echnology of the year. , Keeping up to speed ,Acc...
Other Biology Technology:UN committee opposes human cloning 2UN committee opposes human cloning 3Midwest is cost-effective for startup biotech companies 2Midwest is cost-effective for startup biotech companies 3Midwest is cost-effective for startup biotech companies 4Wisconsin CIOs look for an IT tipping point 2Wisconsin CIOs look for an IT tipping point 3
(Date:11/30/2009)...called invasion proteins are crucial for infection... human cells, which stimulates the host cell to ta...ules exert a different function, for example the r...oup,s results have now been published in the curre..., Spoiled meat is one of the sources for Lister...
(Date:11/30/2009)... obstacle to HIV research is the virus,s exquisite...cientists, traditional tools, like the humble lab ...a team of researchers writing in BioMed Central,s ...nious assault on this problem by creating a mouse ...ng infected with HIV. , George Kassiotis, from t...
(Date:11/30/2009)... , VILNIUS, Lithuania, Nov. 30 /PRNewswire/...om ), a provider of high-precision biometric ident...des in the company,s core product line: VeriLook ...ognition and MegaMatcher 3.1 SDK for large-scale...ication systems (AFIS). Expanded capabilities in V...
Breaking Biology News(10 mins):It takes 2 to infect 2A reductionist approach to HIV research 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Liver Cancer Patients May Get Hope 59093 1Liver Cancer Patients May Get Hope 59093 2Potential Pieces of Autism Puzzle Revealed 59089 1Potential Pieces of Autism Puzzle Revealed 59089 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 1BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 3
...ch 31, 2008 - Biofuels are widely considered one o...y policy makers and environmentalists alike. Howev... are developed and implemented, certain biofuels w...biodiversity the very opposite of what is desired...ly used biofuel in the United States, but it is al...
...rown University] Leading academics and practition...the latest advances in bioengineering research and...ans from ink jets and a new, injectable method for... by Brown University April 4-6, 2008. , It is the...east Bioengineering Conference, which will take pl...
... general anaesthetics to be used by the medical pr...thats puzzled doctors for more than 150 years how...escribed as true serendipity made by Leeds Univers...lue that may unravel the enigma of general anaesth...rations of anaesthetics without harmful side effec...
Other Biology News:Study finds concerns with biofuels 2Brown hosts regional bioengineering conference 2Chloroform provides clue to 150 year old medical puzzle 2
...lock Moto Alpha unit with motorized heated lid and...ul for microarrays and chips. The four screw-down ...s. The sealing force of the motorized lid is set w...atable results. This interchangeable Moto Alpha un...
Skirted Tubes, 2.0 ml, nonsterile, separate screwcaps, 500 from Bio-Rad
...ides labware carriers to suit the widest possible ...nce laboratory. Labware carriers can be placed at ...for the user, thanks to a numbered grid system tha...ion. This allows easy removal of the carriers with...
Affi-Prep Protein A Support, 25 ml from Bio-Rad
Biology Products: